Please go to the PowerPak homepage
and select a course.
Invasive Mycoses: Evaluating the Emerging Paradigms and Their Practical Implications
This activity is jointly provided by Postgraduate Institute for Medicine; Terranova Medica, LLC; and The Mycoses Study Group Education & Research Consortium.
This activity is supported by independent educational grants from Astellas; Merck & Co, Inc; Gilead Sciences Europe, Ltd; and T2 Biosystems.
Peter G. Pappas, MD, FACP
William E. Dismukes Professor of Medicine
Principal Investigator, Mycoses Study Group
Division of Infectious Diseases
University of Alabama at Birmingham
Maiken Cavling Arendrup, Prof, MD, PhD, DMSc
Head, Mycology Unit
Microbiology & Infection Control
Statens Serum Institut
Elizabeth S. Dodds Ashley, PharmD, MHS
Duke Antimicrobial Stewardship Outreach Network
Duke University Medical Center
Durham, North Carolina
Thomas F. Patterson, MD, FACP
Professor of Medicine and Chief, Division of Infectious Diseases
University of Texas Health Science Center
Director, San Antonio Center for Medical Mycology
San Antonio, Texas
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CPE activity:
PETER G. PAPPAS, MD, FACP
Astellas; Cidara Therapeutics; Gilead Sciences; IMMY; Merck & Co, Inc.; T2 Biosystems; Viamet
Cidara Therapeutics; Matinas BioPharma; T2 Biosystems; Viamet; Vical; Amplyx; Scynexis
ELIZABETH S. DODDS ASHLEY, PharmD
Up to Date
Hospital Association of New York State
SPEAKER'S BUREAU, FACULTY, PEER REVIEWER:
New York State Council of Health System Pharmacists
MAIKEN CAVLING ARENDRUP, PROF, MD, PhD, DMSc
Basilea; Gilead; T2 Biosystems
SPEAKER'S BUREAU, FACULTY, PEER REVIEWER:
Astellas; Basilea; Gilead; Merck; Novartis; Pfizer; T2 Biosystems
THOMAS F. PATTERSON, MD, FACP
Amplyx Pharmaceuticals; Astellas; Cidara Therapeutics; Pfizer; Revolution Medicines; Toyama; Viamet; Vical
Astellas; Revolution Medicines
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CPE activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Lisa A. Tushla, PhD, H(ASCP), of Terranova Medica, LLC, reports no financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Postgraduate Institute for Medicine designates this continuing education activity for 2.5 contact hours (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
Credits: 2.5 hours (0.25 ceu)
Published: November 1, 2016
Expires: November 1, 2017
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 150 minutes
This accredited activity has been designed for pharmacists.
HOW TO EARN CREDIT
During the period November 1, 2016 through November 1, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 75% or higher), your Statement of Participation will be made available immediately. Click on View Statement of Participation and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
The goal of this activity is to support clinical pharmacists in their efforts to serve as expert members of the interdisciplinary care team in managing invasive fungal disease and improving patient outcomes.
Upon completion of this activity, participants should be better able to:
- Compare available and emerging diagnostics for the early diagnosis and management of invasive fungal disease
- Evaluate therapeutic options for IFD management in terms of level of evidence and appropriateness in different populations
- Choose treatments that will optimize the pharmacologic aspects of antifungal therapy
- Select appropriate evidence-based antifungal diagnostics and therapies based on specific patient characteristics
- Provide accurate and appropriate counsel as part of the treatment team
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.